|
Synonyms: IMC-CS4
Compound class:
Antibody
Comment: LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R. It is being investigated for its potential anti-neoplastic action. LY3022855 is claimed in patent WO2011123381 [1], by Imclone Llc.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Antibodies claimed in WO2011123381 block CSF-1 and IL-34 binding to the CSF1R, and prevent the dimerization of the receptor required for phosphorylation of the intracellular tyrosine residues, functions which are critical in preventing macrophage induced tumor growth. The claimed antibodies also induce internalisation and degradation of CSF1Rs, and importantly enhance antibody-dependent cell-Mediated cytotoxicity (ADCC) activity by stimulating the killing of tumour cells and tumour-associated macrophages (TAMs) and monocytes [1]. In vitro, LY3022855/IMC-CS4 triggers depletion of TAMs. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
